VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ATRA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ATRAAtara Biotherapeutics, Inc.
$7.87$71M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksATRAEarnings History

ATRA logoAtara Biotherapeutics, Inc. (ATRA) Earnings History

Net Loss

14 years of earnings data (2012–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$17M
● Net Loss
TTM EPS (Diluted)
$-1.11
Per share, diluted
YoY EPS Growth
+122.5%
Excellent
Net Margin
27.1%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin29.7%
Gross Margin82.4%
Return on EquityN/A
Return on Assets50.5%
Record Annual Net Income$33MFY2025
Record Quarterly EPS$4.50Q2 2022
Consecutive Profitable Years1years
Q2 2026
Net Income-$5M
EPS (Diluted)$-0.32
YoY Growth+122.5%Excellent
QoQ Growth-16.6%Declining

Loading earnings history...

Atara Biotherapeutics, Inc. (ATRA) Earnings Overview

As of November 8, 2026, Atara Biotherapeutics, Inc. (ATRA) reported trailing twelve-month net income of -$17M, reflecting +122.5% year-over-year growth. The company earned $-1.11 per diluted share over the past four quarters, with a net profit margin of 27.1%.

Looking at the long-term picture, ATRA's historical earnings data spans multiple years. The company achieved its highest annual net income of $33M in fiscal 2025, representing a new all-time high.

Atara Biotherapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including FATE (-$124M net income, -2051.1% margin), ADCT (-$97M net income, -175.3% margin), CABA (-$190M net income), ATRA has outperformed on profitability metrics. Compare ATRA vs FATE →

ATRA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ATRA logoATRACurrent
-$17M$-1.1127.1%-+122.5%—
FATE logoFATE
-$124M$-1.01-2051.1%-51.8%+29.9%
ADCT logoADCT
-$97M$-0.63-175.3%-+30.9%
CABA logoCABA
-$190M$-1.01--127.0%+29.9%
IMVT logoIMVT
-$538M$-2.62--64.8%-1.5%
RCUS logoRCUS
-$445M$-3.49-142.9%-63.3%-4.8%
Best in group
Lowest in group

ATRA Historical Earnings Data (2012–2025)

14 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$33M+138.3%$36M$2.5727.1%29.7%
2024-$85M+69.1%-$83M$-11.41-66.2%-64.7%
2023-$276M-20.9%-$276M$-65.18-3220.9%-3219.5%
2022-$228M+32.9%-$281M$-55.96-359.1%-441.2%
2021-$340M-10.9%-$340M$-90.78-1672.3%-1673.9%
2020-$307M-5.4%-$309M$-103.63--
2019-$291M+87.4%-$296M$-141.78--
2018-$2.31B-93.1%-$237M$-131.64--
2017-$1.19B-51.2%-$122M$-100.03--
2016-$790M-38.1%-$81M$-68.78--
2015-$572M-104.3%-$58M$-55.92--
2014-$280M-219.2%-$28M$-140.42--
2013-$88M+28.8%-$9M$-227.09--
2012-$123M--$3M$-16.81--

Download Data

Export ATRA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open ATRA Terminal

ATRA Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

14+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ATRA — Frequently Asked Questions

Quick answers to the most common questions about buying ATRA stock.

What is ATRA earnings per share (EPS)?

ATRA trailing twelve-month (TTM) diluted EPS is $-1.11, reflecting +122.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2012 to 2025 is available in the table on this page.

What is Atara Biotherapeutics, Inc.'s net income?

Atara Biotherapeutics, Inc. (ATRA) trailing twelve-month net income is $-17M as of 2025. Earnings grew +122.5% year-over-year.

Is ATRA profitable?

ATRA is not currently profitable on a TTM basis, reporting a net loss of $-17M. Net margin is +27.1%. Investors should monitor for a return to profitability.

What is ATRA's earnings growth rate?

ATRA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2012 to 2025.

What are ATRA's profit margins?

Atara Biotherapeutics, Inc. net profit margin is +27.1%, operating margin is +29.7%, and gross margin is +82.4%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.

Is ATRA growing earnings?

Yes, ATRA earnings are accelerating — EPS growth of +122.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-17M. Earnings momentum is strengthening.

What was ATRA's best earnings year?

Atara Biotherapeutics, Inc.'s highest annual net income on record is $33M, achieved in fiscal year 2025. Earnings history on this page spans 2012 to 2025 and includes all annual and quarterly figures.

What were ATRA's earnings last quarter?

ATRA's most recent reported quarter was Q2 2026. Net income was $-5M with diluted EPS of $-0.32. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ATRA Earnings Over Time (2012–2025)

Net income & EPS — annual and quarterly view